Can this covid-times saviour navigate the self-inflicted deep slump?
The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
Activist Starboard Trailed Peers With Less Than 5% Returns
Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...
Pfizer names former FDA director as chief medical officer
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Alight chairman William Foley to step down, Russell Fradin to succeed
Alight (ALIT) announced that its board of directors appointed Russell Fradin as its chairman of the board of directors, succeeding William ...
The Bakersfield Californian15d
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ...
PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer’s Board of ...
Seeking Alpha16d
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 ...
Mena FN17d
The Industry Veteran CEO: Friend Or Foe?
Starboard woos former Pfizer CEO and CFO In October 2024, Starboard said that former Pfizer CEO Ian Read and former CFO Frank D'Amelio shared concerns about Pfizer's direction and had offered to ...